Novo Nordisk, a competitor in the weight loss pill market, has an oral pill that works better but has more restrictions than Eli Lilly's.
Source Post
Great News for Eli Lilly Stock Investors!
Apr 15, 2026
Eli Lilly's stock is up over 4% following the FDA approval of its weight loss pill. The author, who has held a buy rating on the stock for over a year, discusses the competitive landscape with Novo Nordisk, the pill's convenience factor, and potential pricing strategies. Despite concerns about a brewing price war, the author maintains a bullish outlook, citing a fair value of $1,400 per share based on DCF valuation and attractive forward P/E ratio.
Linked Mentions
Tickers discussed in this post
Eli Lilly stock is a buy with a fair value of $1,400 based on DCF valuation and attractive forward P/E, despite competition and potential price wars.
Linked Signals
Tracked calls opened from this post
LLYbuy opened Apr 15, 2026
+27.42%